HERV-W Env, is expressed in MS lesions and thought to contribute to chronic inflammation and neuronal damage. Temelimab’s neutralization of this protein aims to reduce neuroinflammation, protect oligodendrocytes, and potentially promote remyelination. This approach represents a novel strategy targeting a non-conventional pathogenic factor in MS, with clinical trials focusing on its impact on disease progression and biomarkers.